National Infusion Center Association (NICA)’s Post

Breaking News: Eli Lilly and Company announced today that the U.S. Food and Drug Administration approved Kisunla (donanemab) for Alzheimer’s disease (AD) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of the disease. This approval provides hope for people living with early symptomatic Alzheimer’s disease and their loved ones. With this approval, appropriate patients now have an additional treatment option to treat their Alzheimer’s disease. Read the press release from Eli Lilly here: https://lnkd.in/gADVZ9jQ #InfusionProvider #MedicalProvider #Infusion #InfusionCenter #InfusionNurse #InfusionDeliveryChannel #MedicalInfusionProvider #FutureOfHealthcare

Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease | Eli Lilly and Company

Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease | Eli Lilly and Company

investor.lilly.com

To view or add a comment, sign in

Explore topics